A total of 177 (15%) patients received G-CSF after their first episode of G3-4 neutropenia; 128 (23%) in the FOLFOXIRI/bevacizumab arm and 49 (8%) in the doublets/bevacizumab arm. This evidence concerns the gene CSF3 and neutropenia.